Get the Stockscreener App
1.81
5.73%
-0.11
After Hours:
1.81
Advanced Biomed Inc stock is traded at $1.81, with a volume of 86,395.
It is down -5.73% in the last 24 hours and down -53.47% over the past month.
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
See More
Previous Close:
$1.92
Open:
$1.92
24h Volume:
86,395
Relative Volume:
2.58
Market Cap:
$39.60M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.56%
1M Performance:
-53.47%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.76
$2.151
1-Week Range:
$1.47
$2.20
52-Week Range:
$1.47
$4.00
Advanced Biomed Inc Stock (ADVB) Company Profile
Name
Advanced Biomed Inc
Sector
Industry
Phone
86-21-20510823
Address
401 RYLAND ST, RENO
Compare ADVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADVB
Advanced Biomed Inc
|
1.81 | 39.60M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Advanced Biomed Inc Stock (ADVB) Latest News
Harbour BioMed Reports Full Year 2024 Financial Results - Yahoo Finance
Mainz enrols first subject in study to evaluate colorectal cancer test - Yahoo Finance
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - Yahoo Finance
Advanced Instruments to Acquire and Merge with Nova Biomedical - Contract Pharma
Biomedical Engineering Courses: Admission 2025, Fees, Eligibility, Entrance Exams, Syllabus/Subjects, Top Colleges, Career Scope & Salary - Shiksha
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies - PR Newswire
Advanced Biomed Inc. Completes Successful IPO Launch - TipRanks
Revolutionizing Biomedical Research: Unveiling the Power of Microphysiological Systems with Advanced Assays, Integrated Sensor Technologies, and Real-Time Monitoring - ACS Publications
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket - Benzinga
Red-hot market supports two med-tech IPOs in a day - BioWorld Online
A Dynamic Duo: Travis Stancil and Natella Devitskya Celebrate Five Years of Captivating Performances - The Manila Times
Advanced Biomed Inc. Announces Closing of Initial Public Offering Raising $6.56 Million - Nasdaq
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering - Morningstar
Advanced Biomed prices IPO at $4 per share - MSN
Advanced Biomed Prices 1.6 Million Shares to Raise $6.6 Million in IPO - MarketScreener
OverDrive Appoints Eric Miller to Lead the Company's Data and Information Science Services - The Manila Times
ADVB IPO NewsTaiwanese diagnostics developer Advanced Biomed prices downsized US IPO at the $4 low end - Renaissance Capital
Advanced Biomed Inc. Announces Pricing of Initial Public Offering - GlobeNewswire
This Cancer Detection Biotech Just Priced Its Nasdaq IPOKey Details Inside - StockTitan
Can Mainz Biomed's 82% Detection Rate Technology Revolutionize Colorectal Cancer Prevention? - StockTitan
IPO Roundup: Advanced Biomed, Brag House Holdings and more - MSN
HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies - BioSpace
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development - PR Newswire
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development - GlobeNewswire
Mainz Biomed Launches Major U.S. Study for AI-Powered Colorectal Cancer Detection Test - Stock Titan
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab - Yahoo Finance
Orchestra BioMed shares get shot in the arm on solid clinical trial data - Mugglehead Magazine
Mainz Biomed Enters Agreement with Quest Diagnostics to Advance ColoAlert Colorectal Cancer Screening Test - Nasdaq
Fluid Biomed Inc. Raises $27 Million USD in Oversubscribed Series A Financing to Advance World’s First Bioabsorbable Polymer-Based Stent To Treat Brain Aneurysms - Business Wire
Advanced Biomedical Material Design to Toxicity - ResearchGate
FBB Biomed partners with Verici Dx to advance research on neurologic diseases - Corridor Business Journal
Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - citybuzz -
Mainz Biomed Partners with Thermo Fisher to Advance Colorectal Cancer Screening - Contract Pharma
L&K BIOMED Announces FDA Approval of the BluEX Lumbar Expandable Cage System, Featuring Advanced Surface Technology for Comprehensive Spine Interbody Fusion Options. - Becker's Spine Review
Advanced Biomed dramatically downsizes proposed IPO to $9.4M - MSN
Taiwanese diagnostics developer Advanced Biomed slashes deal size by 92% ahead of $9 million US IPO - renaissancecapital.com
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Thermoelectric Materials and Devices for Advanced Biomedical ApplicationsJia2024Small - Wiley Online Library
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors - PR Newswire
Roche and BARDA: partnering for better brain health - Roche
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies - Bayer
Curi Bio’s Growth Propels Move to Prime Seattle Location to Advance Cutting-Edge Drug Discovery Research - Business Wire
(PDF) Polysaccharide-Based Hydrogels for Advanced Biomedical Engineering Applications - ResearchGate
Polysaccharide-Based Hydrogels for Advanced Biomedical Engineering Applications - ACS Publications
Medical Device Maker Nova Biomedical Is Exploring a Sale - Bloomberg
Genexys BioMed Awarded $320K SBIR Grant to Advance Novel Cystic Fibrosis Gene Therapy - PR Newswire
Biomedical applications of functional hydrogels: Innovative developments, relevant clinical trials and advanced products - ScienceDirect.com
Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test - Proactive financial news
Mainz Biomed seeks FDA’s Breakthrough Devices Designation for advanced colorectal cancer test - News-Medical.Net
NASDAQ – Stock Price, Charts and News Today - BNN Bloomberg
Advanced Biomed Inc Stock (ADVB) Financials Data
There is no financial data for Advanced Biomed Inc (ADVB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):